These findings suggest that CTHRC1 upregulation adversely affects PC prognosis and immune function, suggesting that targeting CTHRC1 could modulate the tumor microenvironment and improve therapeutic outcomes (Zhou et al., 2019). Here, CTHRC1 is linked to neoplasm.